These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

554 related items for PubMed ID: 12518327

  • 21. In prostatism patients the ratio of human glandular kallikrein to free PSA improves the discrimination between prostate cancer and benign hyperplasia within the diagnostic "gray zone" of total PSA 4 to 10 ng/mL.
    Kwiatkowski MK, Recker F, Piironen T, Pettersson K, Otto T, Wernli M, Tscholl R.
    Urology; 1998 Sep; 52(3):360-5. PubMed ID: 9730444
    [Abstract] [Full Text] [Related]

  • 22. Insulin-like growth factor-binding protein-2 in patients with prostate carcinoma and benign prostatic hyperplasia.
    Ho PJ, Baxter RC.
    Clin Endocrinol (Oxf); 1997 Feb; 46(2):145-54. PubMed ID: 9135695
    [Abstract] [Full Text] [Related]

  • 23. Serum BPSA outperforms both total PSA and free PSA as a predictor of prostatic enlargement in men without prostate cancer.
    Canto EI, Singh H, Shariat SF, Lamb DJ, Mikolajczyk SD, Linton HJ, Rittenhouse HG, Kadmon D, Miles BJ, Slawin KM.
    Urology; 2004 May; 63(5):905-10; discussion 910-1. PubMed ID: 15134977
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. The ratio of free to total serum prostate specific antigen and its use in differential diagnosis of prostate carcinoma in Japan.
    Egawa S, Soh S, Ohori M, Uchida T, Gohji K, Fujii A, Kuwao S, Koshiba K.
    Cancer; 1997 Jan 01; 79(1):90-8. PubMed ID: 8988731
    [Abstract] [Full Text] [Related]

  • 27. Clinical usefulness of serum antip53 antibodies for prostate cancer detection: a comparative study with prostate specific antigen parameters.
    Suzuki H, Akakura K, Igarashi T, Ueda T, Ito H, Watanabe M, Nomura F, Ochiai T, Shimada H.
    J Urol; 2004 Jan 01; 171(1):182-6. PubMed ID: 14665872
    [Abstract] [Full Text] [Related]

  • 28. Free to total prostate-specific antigen (PSA) ratio is superior to total-PSA in differentiating benign prostate hypertrophy from prostate cancer.
    Van Cangh PJ, De Nayer P, Sauvage P, Tombal B, Elsen M, Lorge F, Opsomer R, Wese FX.
    Prostate Suppl; 1996 Jan 01; 7():30-4. PubMed ID: 8950361
    [Abstract] [Full Text] [Related]

  • 29. Molecular forms of prostate-specific antigen and human kallikrein 2 (hK2) in urine are not clinically useful for early detection and staging of prostate cancer.
    Pannek J, Rittenhouse HG, Evans CL, Finlay JA, Bruzek DJ, Cox JL, Chan DW, Subong EN, Partin AW.
    Urology; 1997 Nov 01; 50(5):715-21. PubMed ID: 9372881
    [Abstract] [Full Text] [Related]

  • 30. Prostate specific antigen density for discriminating prostate cancer from benign prostatic hyperplasia in the gray zone of prostate-specific antigen.
    Uno H, Koide T, Kuriyama M, Ban Y, Deguchi T, Kawada Y.
    Hinyokika Kiyo; 1999 Jul 01; 45(7):457-61. PubMed ID: 10466060
    [Abstract] [Full Text] [Related]

  • 31. Free to complexed PSA ratio in differentiating benign prostate hyperplasia from prostate cancer.
    Filella X, Alcover J, Corral JM, Molina R, Beardo P, Ballesta AM.
    Anticancer Res; 2001 Jul 01; 21(5):3717-20. PubMed ID: 11848550
    [Abstract] [Full Text] [Related]

  • 32. A multicenter clinical trial on the use of alpha1-antichymotrypsin-prostate-specific antigen in prostate cancer diagnosis.
    Lein M, Jung K, Hammerer P, Graefen M, Semjonow A, Stieber P, Ossendorf M, Luboldt HJ, Brux B, Stephan C, Schnorr D, Loening SA.
    Prostate; 2001 May 01; 47(2):77-84. PubMed ID: 11340629
    [Abstract] [Full Text] [Related]

  • 33. Screening for prostate cancer in 2008 II: the importance of molecular subforms of prostate-specific antigen and tissue kallikreins.
    Jansen FH, Roobol M, Jenster G, Schröder FH, Bangma CH.
    Eur Urol; 2009 Mar 01; 55(3):563-74. PubMed ID: 19058905
    [Abstract] [Full Text] [Related]

  • 34. [Vascular endothelial growth factor and insulin-like-growth factors in prostate cancer. ].
    Trapeznikova MF, Shibaeva AN, Ianshin AA, Urenkov SB, Mironova OS, Kazantseva IA, Kushlinskiĭ NE.
    Urologiia; 2004 Mar 01; (1):17-21. PubMed ID: 15022438
    [Abstract] [Full Text] [Related]

  • 35. Usefulness of proprostate-specific antigen in the diagnosis of prostate cancer.
    Filella X, Alcover J, Molina R, Luque P, Corral JM, Augé JM, Coca F.
    Anticancer Res; 2007 Mar 01; 27(1B):607-10. PubMed ID: 17348449
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37. Stability of free and total prostate specific antigen in serum from patients with prostate carcinoma and benign hyperplasia.
    Paus E, Nilsson O, Børmer OP, Fosså SD, Otnes B, Skovlund E.
    J Urol; 1998 May 01; 159(5):1599-605. PubMed ID: 9554362
    [Abstract] [Full Text] [Related]

  • 38. Comparison of chromogranin A, insulin-like growth factor 1 and prostate-specific antigen serum markers in prostate adenocarcinoma and benign prostatic hyperplasia.
    Sciarra A, Gentile V, Monti S, Dattilo C, Autran Gomez A, Salciccia S, Pannunzi LP, Toscano V, Di Silverio F.
    Urol Int; 2008 May 01; 80(1):68-73. PubMed ID: 18204237
    [Abstract] [Full Text] [Related]

  • 39. Three new serum markers for prostate cancer detection within a percent free PSA-based artificial neural network.
    Stephan C, Xu C, Brown DA, Breit SN, Michael A, Nakamura T, Diamandis EP, Meyer H, Cammann H, Jung K.
    Prostate; 2006 May 01; 66(6):651-9. PubMed ID: 16388506
    [Abstract] [Full Text] [Related]

  • 40. Preoperative blood reverse transcriptase-PCR assays for prostate-specific antigen and human glandular kallikrein for prediction of prostate cancer progression after radical prostatectomy.
    Shariat SF, Gottenger E, Nguyen C, Song W, Kattan MW, Andenoro J, Wheeler TM, Spencer DM, Slawin KM.
    Cancer Res; 2002 Oct 15; 62(20):5974-9. PubMed ID: 12384565
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 28.